• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

BioMarin Files Aryplase BLA;EU Filing To Follow This Year

Nov. 30, 2004
By Aaron Lorenzo
BioMarin Pharmaceutical Inc. moved Aryplase (galsulfase) into the FDA's hands, filing for approval of the enzyme-replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), an inherited and life-threatening disease for which no drug therapies are available. (BioWorld Today)
Read More

Cubist Raises More Than $104M In Public Offering

Nov. 24, 2004
By Aaron Lorenzo
Cubist Pharmaceuticals Inc. raised more than $100 million through a larger public offering of its common shares than originally expected. (BioWorld Today)
Read More

Cubist Raises More Than $104M In Public Offering

Nov. 24, 2004
By Aaron Lorenzo
Cubist Pharmaceuticals Inc. raised more than $100 million through a larger public offering of its common shares than originally expected. (BioWorld Today)
Read More

New AGI-1067 Data Good, But Less So Than Previous

Nov. 23, 2004
By Aaron Lorenzo

New AGI-1067 Data Good, But Less So Than Previous

Nov. 23, 2004
By Aaron Lorenzo

OSI, Genentech Receive FDA Approval Of Tarceva For NSCLC

Nov. 22, 2004
By Aaron Lorenzo
The FDA approved a new lung cancer drug, Tarceva (erlotinib), but a surprise in the agency's authorization might have driven down share values in the companies that developed it - OSI Pharmaceuticals Inc. and Genentech Inc. (BioWorld Today)
Read More

OSI, Genentech Receive FDA Approval Of Tarceva For NSCLC

Nov. 22, 2004
By Aaron Lorenzo
The FDA approved a new lung cancer drug, Tarceva (erlotinib), but a surprise in the agency's authorization might have driven down share values in the companies that developed it - OSI Pharmaceuticals Inc. and Genentech Inc. (BioWorld Today)
Read More

ISTA Acquiring Dry Eye Drug Rights From Old Friend Senju

Nov. 19, 2004
By Aaron Lorenzo

ISTA Acquiring Dry Eye Drug Rights From Old Friend Senju

Nov. 19, 2004
By Aaron Lorenzo

Committee Probes Flu Vaccine Shortage, Seeks Plan For 2005

Nov. 18, 2004
By Aaron Lorenzo
Previous 1 2 … 119 120 121 122 123 124 125 126 127 … 237 238 Next

Popular Stories

  • Telomeres and DNA illustration

    23andme founder-led group outbids Regeneron for company

    BioWorld
    The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
  • Today's news in brief

    BioWorld
    BioWorld briefs for June 17, 2025.
  • Sarepta signage

    Elevidys’ second liver death hits Sarepta, sends DMD ripples

    BioWorld
    How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 17, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe